Kidney transplantation in patients on anti‐tubercular therapy: A single centre observational study
Male
Adult
Graft Rejection
Graft Survival
Antitubercular Agents
Middle Aged
Kidney Transplantation
Pyrazinamide
Young Adult
Treatment Outcome
0302 clinical medicine
Humans
Tuberculosis
Kidney Failure, Chronic
Female
Rifampin
Ethambutol
Retrospective Studies
DOI:
10.1111/tid.14242
Publication Date:
2024-01-25T09:49:04Z
AUTHORS (6)
ABSTRACT
Abstract Background Tuberculosis (TB) is a common infection in chronic kidney disease. The prolonged therapy of TB can delay transplantation patients on antitubercular (ATT). Methods This was retrospective single‐center study to analyze the safety and its outcomes undergoing while continuation phase ATT. Results Between 2013 2022, 30 underwent Median age 38 years 70% were males. Majority (86.7%) had extrapulmonary tuberculosis, most site involvement being tubercular lymphadenitis. 14/30 microbiological/histopathological diagnosis rest diagnosed by ancillary tests. Patients treated with 4 drug ATT (isoniazid, rifampicin, pyrazinamide, ethambutol) before for aminimum 2 months. Post‐transplantation fluoroquinolone‐based non‐rifamycin used (median duration 11 months). All completed therapy. At years, there 100% patient survival 96.7% graft survival. eGFR at 6, 12, 24 months post‐transplantation 71.9, 64.7, 67 mL/min/1.73m , respectively. percentage suffering biopsy proven acute rejection 3.3%, 6.7%, 6.7%. Conclusion Kidney be done who have satisfactory response intensive decision should individualized. In our experience, excellent these low risk failure or relapse TB. image
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....